CBDXFund

About

Cannabinoid Biosciences Inc. (CBDZ) is a California based biopharmaceutical company whose mission is to revolutionize and standardize the pharmaceuticals and non-pharmaceutical CBD products across the CBD market in the United States of America and to some extent, globally. CBDZ is stepping in to standardize this market, establish process control (Benchmark), and create formulation standards for the industry. CBDZ controls the production and distribution of verities of consumer cannabidiol (CBD) formulation under private brands in the United States. CBDZ’s goal is to bring standardization to the CBD industry, the same way that John D Rockefeller’s Standard Oil brought standardization to crude refining in the United States in the nineteenth century.
GET IN ON THE GROUND FLOOR OF CBD/HEMP/CANNABIS INVESTMENT WITH SHARES OF CBDZ COMMON STOCK @ $10 PER SHARE

Cannabinoid Biosciences Inc. (CBDZ) is the first-female controlled CBD IPO in the United States and Canada.

CBDZ Common Stock has been registered with the SEC under Reg. A+, to be sold at $10 per share.

The minimum investment is $100 for 10 shares.

CBDZ has agreed to buy 10 dispensaries with $54 million in annual revenue from their current owners for $49 million. The consolidation rollup would do IPO on the NASDAQ or NYSE and Canadian Securities Exchange (CSE).

Once CBDZ successfully listed on the NASDAQ, a $1,000 investment could fetch a lot more because NASDAQ and NYSE market-participants pay $131 - $215 for $1 of sale for rollup/consolidated Cannabis business.

Featured Products